In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Urogen Pharma, with a price target of $50.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors including the successful completion of patient enrollment in UroGen Pharma’s Phase 3 UTOPIA clinical trial for UGN-103. This trial is a crucial step in the company’s strategy for managing the lifecycle of its products, particularly for treating recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The proprietary RTGel technology used in UGN-103 is expected to offer significant improvements over existing treatments, which could lead to FDA approval by 2027, thereby enhancing UroGen’s long-term commercial success.
Additionally, the recent FDA approval of ZUSDURI, which is UGN-102, marks a significant milestone as it is the first and only approved treatment for recurrent LG-IR-NMIBC. This approval, based on strong clinical trial results, positions UroGen Pharma favorably in the market. The company’s revenue forecasts for 2025 and 2026 have been revised upwards, reflecting the anticipated commercial success of its products. These developments suggest a promising financial outlook for UroGen, supporting the Buy rating and a 12-month price target of $50.